Get the Stockscreener App
1.159
3.48%
0.039
Evogene Ltd stock is traded at $1.159, with a volume of 33,900.
It is up +3.48% in the last 24 hours and up +4.41% over the past month.
Evogene Ltd is a computational biology company targeting to revolutionize product development for life-science based industries, including human health, agriculture, and industrial applications. The company established its technology, the Computational Predictive Biology (CPB) platform. The CPB platform is designed to computationally discover and develop life-science products based on microbes, small molecules, and genetic elements as the core components for such products. It holds several subsidiaries utilizing the CPB platform for the development of human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits, and ag-solutions for castor oil production. It generates maximum revenue from the Agriculture segment, followed by Industry.
See More
Previous Close:
$1.12
Open:
$1.13
24h Volume:
33,900
Relative Volume:
0.44
Market Cap:
$9.94M
Revenue:
$6.74M
Net Income/Loss:
$-14.74M
P/E Ratio:
-0.5153
EPS:
-2.2491
Net Cash Flow:
$-18.31M
1W Performance:
+23.35%
1M Performance:
+4.41%
6M Performance:
-13.51%
1Y Performance:
-37.35%
1-Day Range:
$1.13
$1.21
1-Week Range:
$0.9303
$1.21
52-Week Range:
$0.93
$2.42
Evogene Ltd Stock (EVGN) Company Profile
Compare EVGN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EVGN
Evogene Ltd
|
1.1401 | 9.76M | 6.74M | -14.74M | -18.31M | -2.2491 |
|
VRTX
Vertex Pharmaceuticals Inc
|
467.21 | 113.87B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
773.83 | 80.22B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
405.25 | 52.56B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
802.32 | 49.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
174.76 | 37.37B | 447.02M | -1.18B | -906.14M | -6.1812 |
Evogene Ltd Stock (EVGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-08-21 | Initiated | ROTH Capital | Buy |
| Jul-29-21 | Initiated | Aegis Capital | Buy |
| Dec-01-20 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-16-13 | Initiated | Oppenheimer | Outperform |
Evogene Ltd Stock (EVGN) Latest News
Evogene (NASDAQ:EVGN) Stock Passes Below Fifty Day Moving Average – Time to Sell? - Defense World
Panic Selling: Will Evogene Ltd stock remain a Wall Street favorite2025 Price Targets & Low Drawdown Trading Strategies - moha.gov.vn
Evogene Appoints Dr. Olga Nissan as Vice President of Business Development to Drive AI-Driven Growth - The Globe and Mail
Evogene appoints Dr. Olga Nissan as VP of business development By Investing.com - Investing.com Nigeria
Evogene appoints Nissan as VP of Business Development - TipRanks
Evogene appoints Dr. Olga Nissan as VP of business development - Investing.com
Evogene Announces Appointment of Dr. Olga Nissan as its Vice President of Business Development - Barchart.com
How Evogene Ltd. stock compares to industry benchmarks2025 Support & Resistance & AI Powered Market Trend Analysis - Улправда
Will Evogene Ltd. stock remain a Wall Street favoriteQuarterly Growth Report & Smart Allocation Stock Reports - Bölüm Sonu Canavarı
Is Evogene Ltd. stock resilient to inflationJuly 2025 Setups & Free Daily Entry Point Trade Alerts - Улправда
Will Evogene Ltd. stock benefit from upcoming earnings reportsJuly 2025 Drop Watch & AI Based Trade Execution Alerts - DonanımHaber
Can Evogene Ltd. stock sustain market leadershipWeekly Gains Report & Safe Capital Investment Plans - DonanımHaber
Can Evogene Ltd. stock sustain free cash flow growth2025 Price Momentum & Entry and Exit Point Strategies - DonanımHaber
Should I hold or sell Evogene Ltd. stock in 20252025 Volume Leaders & Technical Buy Zone Confirmation - Улправда
Why Evogene Ltd. stock appeals to dividend seekersJuly 2025 Technicals & Weekly High Conviction Ideas - DonanımHaber
Is Evogene Ltd. stock attractive for growth ETFsBreakout Watch & Intraday High Probability Setup Alerts - Улправда
New Highs: How Evogene Ltd. stock compares to industry benchmarksVolume Spike & Consistent Return Strategy Ideas - Улправда
Will Evogene Ltd. stock keep outperforming rivalsWeekly Stock Recap & Growth Focused Investment Plans - Улправда
Reviewing Vera Therapeutics (NASDAQ:VERA) & Evogene (NASDAQ:EVGN) - Defense World
Will Introduced Innovation Sustain VLS Finance Limiteds GrowthInterest Rate Changes & Superior Trading Strategies - earlytimes.in
Investment Recap: Is Evogene Ltd stock a smart buy before Fed meetingTrade Entry Report & Free Growth Oriented Trading Recommendations - BỘ NỘI VỤ
Evogene (NASDAQ:EVGN) Stock Crosses Below Two Hundred Day Moving Average – Time to Sell? - Defense World
How AI Is Breaking Down the Bottlenecks in Small Molecule Drug Discovery - Unite.AI
Evogene (EVGN) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session - Sahm
Evogene (NASDAQ:EVGN) Share Price Passes Below Two Hundred Day Moving Average – What’s Next? - Defense World
Evogene Announces Completion of Transaction for the Sale of Lavie Bio's Activity to ICL (PR Newswire) - Aktiellt
Evogene shares climb 5% as cost reductions help deliver earnings beat - MSN
Evogene Ltd. Reports Strategic Shift and Financial Results - MSN
Evogene Ltd. Earnings Call: Strategic Shifts and Optimism - The Globe and Mail
Is Evogene Ltd. stock cheap compared to fundamentals - newser.com
Evogene Ltd. (NASDAQ:EVGN) Q3 2025 Earnings Call Transcript - Insider Monkey
Can Evogene Ltd. stock hit record highs again2025 Sector Review & Accurate Entry/Exit Alerts - newser.com
Is Evogene Ltd. stock oversold or undervalued2025 Key Highlights & Free Real-Time Volume Trigger Notifications - newser.com
Evogene: Q3 Earnings Snapshot - Stamford Advocate
Evogene earnings beat by $0.12, revenue fell short of estimates - Investing.com Australia
Evogene Q3 2025 Earnings Call Transcript - MarketBeat
Earnings Call Summary | Evogene(EVGN.US) Q3 2025 Earnings Conference - 富途牛牛
Earnings call transcript: Evogene reports Q3 2025 earnings beat amid restructuring - Investing.com India
Evogene shares rise 5% as cost-cutting measures drive earnings beat - Investing.com Nigeria
Evogene Reports Third Quarter 2025 Financial Results - The AI Journal
Evogene Reports Q3 2025 Financial Results Amid Strategic Shift - TipRanks
Israeli biotech firm Evogene's Q3 revenue misses estimates due to reduced seed sales - TradingView
Evogene shares rise 5% as cost-cutting measures drive earnings beat By Investing.com - Investing.com South Africa
Evogene : Q3 2025 Consolidated Financial Statements - MarketScreener
Evogene Ltd Stock (EVGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.45%
0.43%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):